Abstract
There are three aims for this paper, which are as follows:
-
1.
To show that post-marketing clinical studies are an essential and important part of the life of any medicine.
-
2.
To indicate new possibilities for clinical research following recent moves in the UK to expand computerization of general practice records.
-
3.
To suggest improvements for the safety evaluation of marketed medicines in the future.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
Reference
Snell E S. Post-marketing development of medicines. Pharmacy International 1986;7:33–7.
Hall Gillian C, Luscombe D K, Walker S R. Use of a general practice data base for post-marketing surveillance. Poster presentation at the Sixth International Meeting of Pharmaceutical Physicians, Brighton, England, June 1987.
Editor information
Editors and Affiliations
Copyright information
© 1988 The International Federation of Associations of Pharmaceutical Physicians
About this chapter
Cite this chapter
Snell, E.S. (1988). Exploring the clinical properties of marketed drugs. In: Burley, D., Haward, C., Mullinger, B. (eds) The Focus for Pharmaceutical Knowledge. Palgrave, London. https://doi.org/10.1007/978-1-349-09571-1_19
Download citation
DOI: https://doi.org/10.1007/978-1-349-09571-1_19
Publisher Name: Palgrave, London
Print ISBN: 978-1-349-09573-5
Online ISBN: 978-1-349-09571-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)